Colorectal Cancer:
– Capecitabine is indicated as a single agent for adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred.
– Capecitabine was noninferior to 5fluorouracil and leucovorin (5-FU/LV) for disease-free survival; consider results of combination chemotherapy trials, which have shown improvement in disease-free and overall survival, when prescribing single-agent capecitabine in the adjuvant setting.
Breast Cancer:
– Capecitabine in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.
– Indicated for patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel for whom further anthracycline therapy is not indicated (eg, patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents)
